In a significant breakthrough for the treatment of liver disease, Novo Nordisk's Wegovy has received U.S. approval for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) in ...

This week, medication savings platform GoodRx announced a partnership with Novo Nordisk – the company behind Ozempic and ...

Viking Therapeutics, Inc.'s obesity drug VK2735 results reveal no clear edge over leading competitors. Click for why this ...

Danish drugmaker Novo Nordisk (NVO) on Tuesday said that its blockbuster drug Ozempic is now approved in Canada to reduce the ...

Novo said cash-paying Americans can now buy Ozempic for $499 per month through various channels including its official ...

Health Canada approved Ozempic for type 2 diabetes patients with chronic kidney disease after positive FLOW trial results.

The company’s market value was nearly cut in half following trial results showing higher rates of treatment discontinuations ...

A group of vaccine-skeptical doctors and mandate opponents is challenging the CDC’s childhood immunization schedule in ...

Wegovy is now positioned as the first and only GLP-1 treatment.

Viking Therapeutics stock plunges 37% as trial data sparks concerns over dropout rates and side effects despite weight loss ...

An outbreak of Legionnaires’ disease in City’s Harlem neighborhood thought to have originated in contaminated cooling towers ...

This episode of Pharma Pulse covers Novo Nordisk’s FDA win for Wegovy in MASH-related liver fibrosis, new research on a ...